11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Immunotherapy of Prostate Cancer: Facts and Hopes

      , ,
      Clinical Cancer Research
      American Association for Cancer Research (AACR)

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="P1">In the last few years immunotherapy has become an important cancer treatment modality and while the principles of immunotherapy evolved over many decades, the FDA approvals of sipuleucel-T and ipilimumab began a new wave in immuno-oncology. Despite the current enthusiasm, it is unlikely that any of the immunotherapeutics alone can dramatically change prostate cancer outcomes, but combination strategies are more promising and provide a reason for optimism. Several completed and ongoing studies have shown that the combination of cancer vaccines or checkpoint inhibitors with different immunotherapeutic agents, hormonal therapy (enzalutamide), radiation therapy (radium 223), DNA-damaging agents (olaparib), or chemotherapy (docetaxel) can enhance immune responses and induce more dramatic, long-lasting clinical responses without significant toxicity. The goal of prostate cancer immunotherapy does not have to be complete eradication of advanced disease, but rather the return to an immunologic equilibrium with an indolent disease state. In addition to determining the optimal combination of treatment regimens, efforts are also ongoing to discover biomarkers of immune response. With such concerted efforts, the future of immunotherapy in prostate cancer looks brighter than ever. </p>

          Related collections

          Author and article information

          Journal
          Clinical Cancer Research
          Clin Cancer Res
          American Association for Cancer Research (AACR)
          1078-0432
          1557-3265
          November 14 2017
          November 15 2017
          November 15 2017
          June 29 2017
          : 23
          : 22
          : 6764-6770
          Article
          10.1158/1078-0432.CCR-17-0019
          5690854
          28663235
          50c4bd4a-432c-46f6-ac15-5dc25418cad8
          © 2017
          History

          Comments

          Comment on this article